Inclusion Criteria:

- Man or woman > 18 years of age

- Competent to comprehend, sign, and date an IEC-approved informed consent form

- Histologically or cytologically-confirmed metastatic adenocarcinoma of the colon or
rectum.

- Radiographically documented disease progression per modified RECIST criteria either
while receiving or ≤ 6 months after the last dose of prior first-line chemotherapy
for mCRC

- At least 1 uni-dimensionally measurable lesion of at least 20 mm per modified RECIST
criteria.

- If subject has prior history of cancer other than colorectal carcinoma, basal cell
carcinoma, or cervical carcinoma in situ, then subject must not have had treatment or
active disease within 5 years.

- Prior radiotherapy is acceptable.

- One and only one prior chemotherapy regimen for mCRC consisting of first-line
fluoropyrimidine-based chemotherapy.

- ECOG performance status of 0, 1 or 2

- Life expectancy ≥ 3 months

- Hematologic function:ANC > 1.5 x 109/L, Platelet count > 100 x 109/L, Hemoglobin > 10
g/dL

- Renal function: Creatinine < 1.5 mg/dL

- Hepatic function: AST and ALT < 3 x ULN (if liver metastases < 5 x ULN)

- Bilirubin < 2 x ULN

Exclusion Criteria:

- No more than one prior chemotherapy regimen for mCRC consisting of first-line
fluoropyrimidine-based chemotherapy. (Prior adjuvant fluoropyrimidine-based
chemotherapy is allowed)

- Prior systemic therapy for the treatment of metastatic colorectal carcinoma with the
exception of adjuvant fluoropyrimidine-based chemotherapy given at least 6 months
prior to enrolment.

- Systemic chemotherapy, hormonal therapy, immunotherapy or experimental or approved
proteins/antibodies (eg, bevacizumab) ≤ 30 days before inclusion

- Unresolved toxicities from prior systemic therapy that, in the opinion of the
investigator, does not qualify the patient for inclusion

- Central nervous system/brain metastases

- Significant cardiovascular disease including unstable angina or myocardial infarction
within 6 months before initiating study treatment or a history of ventricular
arrhythmia

- Prior anti-EGFr antibody therapy (eg, cetuximab) or treatment small molecule EGFr
tyrosine kinase inhibitors (eg, erlotinib)

- History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial
pneumonitis or pulmonary fibrosis on baseline chest CT scan

- Treatment for systemic infection within 14 days before initiating study treatment

- Radiotherapy ≤ 14 days prior to inclusion. Patients must have recovered from all
radiotherapy-related toxicities

- Active inflammatory bowel disease or other bowel disease causing chronic diarrhoea
(defined as > 4 loose stools per day)

- History of Gilbert's syndrome or dihydropyrimidine deficiency

- History of any medical condition that may increase the risks associated with study
participation or may interfere with the interpretation of the study results

- Known positive test for human immunodeficiency virus infection, hepatitis C virus,
chronic active hepatitis B infection

- subject allergic to the ingredients of the study medication or to Staphylococcus
protein A

- Any co-morbid disease that would increase risk of toxicity

- Any kind of disorder that compromises the ability of the subject to give written
informed consent and/or comply with the study procedures

- Any investigational agent within 30 days before enrolment

- Must not have had a major surgical procedure within 28 days of randomization

- Subject who is pregnant or breast feeding

- Woman or man of childbearing potential not consenting to use adequate contraceptive
precautions i.e. double barrier contraceptive methods

- Subject unwilling or unable to comply with study requirements